PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced four poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held virtually and at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023.
Poster presentation details:
| Poster Title: | VIP236: A small molecule drug conjugate with an optimized camptothecin payload has significant activity in patient-derived and metastatic cancer models | |
| Abstract Number: | 484 | |
| Presenter: | Beatrix Stelte-Ludwig, PhD | |
| Session Type: | In-Person Poster Presentation | |
| Session Title: | Novel Antitumor Agents 1 | |
| Session Time: | Sunday, April 16, 2023 at 1:30 PM ET | |
| Location: | Poster Section 17; Poster Board Number 15 |
| Poster Title: | Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat MYCN-amplified rhabdomyosarcoma and neuroblastoma in children | |
| Abstract Number: | 1558 | |
| Presenter: | Andy Tran | |
| Session Type: | In-Person Poster Presentation | |
| Session Title: | Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy | |
| Session Time: | Monday, April 17, 2023 at 9:30 AM ET | |
| Location: | Poster Section 15; Poster Board Number 6 |
| Poster Title: | Synthesis and characterization of novel small molecule drug conjugates with different payloads designed to be released in tumor microenvironment by neutrophil elastase | |
| Abstract Number: | 2722 | |
| Presenter: | Hans-Georg Lerchen, PhD | |
| Session Type: | In-Person Poster Presentation | |
| Session Title: | Drug Delivery Systems | |
| Session Time: | Monday, April 17, 2023 at 1:30 PM ET | |
| Location: | Poster Section 15; Poster Board Number 25 |
| Poster Title: | CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma | |
| Abstract Number: | 6294 | |
| Presenter: | Tibor Schomber, PhD | |
| Session Type: | In-Person Poster Presentation | |
| Session Title: | Growth Factor Receptors as Therapeutic Targets | |
| Session Time: | Wednesday, April 19, 2023 at 9:00 AM ET | |
| Location: | Poster Section 21; Poster Board Number 1 |
A copy of the presentation materials can be accessed on the Investors section of the Company’s website at www.vincerx.com once each presentation has concluded.
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. (Vincerx) is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. The company’s diverse pipeline consists of enitociclib, currently in Phase 1, and a proprietary modular bioconjugation platform, which includes a small molecule drug-conjugate, VIP236, in Phase 1, and preclinical next-generation antibody drug conjugates, VIP943 and VIP924.
Vincerx Pharma is based in Palo Alto, Calif., and has a research facility in Monheim, Germany. For more information, please visit www.vincerx.com.
Contacts
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.05 |
| Daily Change: | -0.002 -3.85 |
| Daily Volume: | 7,997 |
| Market Cap: | US$1.820M |
March 18, 2025 January 29, 2025 December 27, 2024 November 12, 2024 October 07, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
